Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Eden vs Dr. Gillis' Wellness Center

Two GLP-1 desks, one scoreboard. We put Eden and Dr. Gillis' Wellness Center head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 3 · Grade A−

Eden

Visit Eden Full brief →
vs
No. 103 · Grade C

Dr. Gillis' Wellness Center

Visit Dr. Gillis' Wellness Center Full brief →

The verdict

Eden takes this head-to-head.

Eden scores 91 to 72 on our six-factor Brief Score — A polished, high-disclosure program with strong nationwide coverage — you pay more, but you know exactly what you're paying for.

That doesn't make Dr. Gillis' Wellness Center a bad call — it's best for patients wanting sublingual odt glp-1 tablets or a needle-free weight-loss option. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
89
36
Supply Reliability
92
76
Transparency
93
88
Access Breadth
90
86
Clinical Oversight
92
84
Track Record
89
78
EdenBrief Score 91 · 72Dr. Gillis' Wellness Center

Price, coverage & the tracker

EdenDr. Gillis' Wellness Center
Brief Score91/100 (A−)72/100 (C)
Semaglutide$239/moFrom $149/mo (starting dose, compounded)
Tirzepatide$349/moNot disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

Eden: Premium line steady; high supply-chain disclosure keeps our confidence high.

Dr. Gillis' Wellness Center: New to the tracker on 1 August 2026. The published line reads From $149/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.